Making your biotech program investor-ready
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
Jim Gallagher2021 年 1 月 21 日
An Introduction to Asset Evaluation for Emerging Biotech Companies
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
Jim Gallagher2021 年 1 月 21 日
“Where do I start?”: Strategies for selecting the first dose for human clinical trials
This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…
Jim Gallagher2020 年 12 月 22 日
The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries
Alison Dillman,1 Michael J Zoratti,2 Jay JH Park,3 Grace Hsu,2 Louis Dron,2 Gerald Smith,2 Ofir Harari,2 Craig R Rayner,4 Noor-E Zannat,2 Alind Gupta,2 Eric Mackay,5 Paul…
Jim Gallagher2020 年 12 月 22 日
Getting Real with RWE
By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…
Jim Gallagher2020 年 11 月 20 日
How PBPK Modeling Can Replace Drug-Drug Interaction Studies
Patients often take more than one drug at a time, especially elderly patients and those…
Jim Gallagher2020 年 11 月 12 日
